One more milestone has been achieved on the front of vaccination against the COVID virus in that children of the age group between 2 to 18 year can now be safely inoculated thanks to the expert panel of the country’s central drug authority duly recommending emergency use authorisation of Covaxin. This vaccine is indigenously manufactured by Hyderabad based Bharat Biotech. In this connection, trials and other investigations having all been conducted in respect of the vaccine and the collected data having been submitted to concerned technical and Regulatory Authorities followed by the Subject Expert Committee on COVID 19 having examined the data and other formalities necessary therewith. The Committee has finally given the market authorisation of the vaccine in respect of the age bracket of 2 to 18 years. Now DCGI has to give its final approval after receiving which it will be the second vaccine to receive Emergency Use Authorisation (EUA). A third potential vaccine for children Novavax by Serum Institute for which the DCGI has cleared the trials for children of the age group of 7to 11 yeas followed by a fourth potential is Corbevax currently undergoing trials all show how much are our medical scientists engaged in finding vaccines against the dreaded virus for all age groups and be among the top countries of the world in fighting the virus.
Trending Now
E-Paper
Follow our WhatsApp channel